HTL Biotechnology and Echelon Biosciences Inc. announce strategic partnership to advance biopolymer platform and hyaluronic acid research tools
14.4.2021 13:00:00 EEST | Business Wire | Press release
HTL, the worldwide leader in biotechnology solutions using hyaluronic acid (HA) and other biopolymers, and Echelon Biosciences Inc., a U.S.-based global supplier of biochemical reagents, assays, and services to research and development laboratories, announced today their new distribution and product development partnership. The partnership will enable distribution of high-quality HA and glycosaminoglycan (GAG), and the co-development of novel GAG products.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210414005119/en/
HTL's campus is located in Paris, France. HTL, the worldwide leader in biotechnology solutions using hyaluronic acid (HA) and other biopolymers, and Echelon Biosciences Inc., a U.S.-based global supplier of biochemical reagents, assays, and services to research and development laboratories, announced today their new distribution and product development partnership. The partnership will enable distribution of high-quality HA and glycosaminoglycan (GAG), and the co-development of novel GAG products. https://htlbiotech.com/
The partnership provides academic research and pharmaceutical development laboratories’ expanded access to Good Manufacturing Practices (GMP)-grade, kit-packaged hyaluronic acid and glycosaminoglycan (GAG) products. By offering premium, clinical grade products to early-stage research investigators, the partnership seeks to bridge the gap between lab-based research, development and commercialization, and accelerate innovation worldwide.
“Innovation is at the heart of HTL’s DNA,” said HTL CEO Yvon Bastard. “This growth opportunity reinforces our mission and vision to apply science for increased bio-compatibility and improved health outcomes around the world.”
“This new partnership offers scientists and researchers the key technologies to develop innovative biopolymer solutions for new medical applications in aesthetics, ophthalmology, rheumatology, tissue engineering and drug delivery,” said Charles Ruban, HTL deputy CEO. “This is the true meaning of HTL’s tagline of ‘Beyond, together.’ HTL’s ambition is not only to grow its lead position in producing and distributing hyaluronic acid worldwide, but also to build tomorrow’s glycosaminoglycan-based solutions.”
“Echelon has been granted the opportunity to expand its market-leading HA assays and extra cellular matrix product line with the supply of HTL’s hyaluronic acid and other GAG-derived products. HTL is recognized internationally for producing biopolymers of premium quality,” says Bert Israelsen, president of Echelon Biosciences. “Echelon offers our customers access to the latest innovative tools with unparalleled technical support, thereby fully enabling maximized creativity in basic and applied research. With its fermentation and organic synthesis platforms, HTL creates functionality and added value by developing chemically modified biopolymers tailored to specific needs.”
“This new partnership is a milestone in HTL’s expanding footprint in the North American market and with the U.S. medical community,” said Glenn Prestwich, Ph.D., one of Echelon’s founders and now HTL’s exclusive science and innovation advisor for this market. By entrusting Echelon with the distribution of HTL’s hyaluronic acid and glycosaminoglycan products for research use, HTL aims to significantly increase its support and involvement in biopolymer research in the U.S. and worldwide, but also its research and development capacity.
“This new initiative demonstrates HTL’s commitment to invest in innovation in healthcare,” said Humberto C. Antunes, strategic advisor to HTL and former CEO of Galderma. “In the fields of health and wellness, the biotechnology ecosystem of innovation, incubators, and established and emerging companies are incredibly dynamic in the United States, Mexico and Canada. It means a huge growth potential for HTL products,” added Antunes.
About HTL
HTL is a biotechnology company, leading the way in the design and production of pharmaceutical grade hyaluronic acid and other innovative functional biopolymers for premium medical products. HTL serves the pharmaceutical and medical device industries worldwide, enabling them to transform lives of patients. HTL’s unsurpassed commitment to client partnership has been consistently proven in the marketplace. The company is recognized for supplying the highest quality products and continually investing in driving and supporting market growth. For over 25 years, its cutting-edge research and development has allowed to develop unique value-driven solutions to meet the innovation needs of its clients.
About Echelon Biosciences, Inc.
Based in Salt Lake City, Utah, Echelon Biosciences, was established in 1997 to supply synthetic lipid reagents for research and development. Since then, Echelon has successfully grown in scale and scope to include custom chemistry, peptides, and biological assays with over 700 catalog items in the fields of cell signaling, extracellular matrix, cancer drug discovery, and disease biomarkers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210414005119/en/
Contact information
HTL
Dianne Danowski Smith, APR – Publix Northwest PR + PA
+1.503.201.7019 - dianne@publixnw.com
Echelon Biosciences, Inc.
Mark Nelson, PhD - Vice President Business and Science Development
+1 801-588-0455 - mnelson@echelon-inc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fourthline and Veridas Join Forces to Fight Identity Fraud with a Global Identity Platform16.7.2026 12:21:00 EEST | Press release
Fourthline, Europe's identity verification and compliance leader, has signed an agreement to merge with Veridas, a recognised international digital identity provider, to deliver the most complete and advanced trust platform across Europe and the Americas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629494028/en/ Paul Stoddart, CEO of Fourthline The combination unites Fourthline's institutional-grade KYC/AML compliance orchestration across Northern and Central Europe with Veridas's proprietary identity and anti-fraud stack and market position in Southern Europe, the US, and Latin America. Operating under a single, integrated AI architecture, the combined entity will secure the entire customer lifecycle for global Tier-1 banks, fintechs, telecommunications providers, and digital disruptors across both continents. Fourthline and Veridas come together from a position of strength, both profitable, EBITDA-positive, and at th
Tax Systems Rebrands as Alphatax16.7.2026 11:00:00 EEST | Press release
Tax Systems, a global tax and accounting software provider, today announced it is rebranding as Alphatax, aligning the company with its flagship corporation tax compliance solution and marking the next stage in its evolution as an AI-first technology business. The rebrand reflects the company's ambition to redefine how tax professionals work through connected, AI-powered technology. As Alphatax, the business is bringing together compliance, data, governance and intelligence into a single platform, creating the foundations for the world’s first tax operating system: a connected environment where tax data, decisions, approvals, filings and evidence can come together. The new identity builds on the strong reputation of Alphatax, a market-leading corporation tax software trusted by tax professionals across the world. Bringing the company’s expanding portfolio together under one master brand will provide customers with a more connected experience across corporate tax, Pillar Two, transfer p
SWISSto12 Closes US$70 Million Series C to Meet Growing Multi-Orbit Demand16.7.2026 10:00:00 EEST | Press release
SWISSto12, a leading enabler of the new space economy, today announced the close of its $70 million (€61 million) Series C. This news follows the award of $84.8 million (€73 million) from European Space Agency (ESA) Member States to the HummingSat ARTES partnership project, through which ESA supports SWISSto12 in the development and in-orbit validation of HummingSat. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716342732/en/ SWISSto12 will scale its manufacturing and integration capacity to meet accelerating demand from commercial and sovereign government customers. The Series C fundraise follows a period of sustained commercial growth for the company, with revenues of $140 million (€121 million) for 2025 and total contract values now exceeding $500 million (€432 million), driving positive EBITDA in 2026. To date, SWISSto12 has secured seven contracts for its HummingSat geostationary (GEO) small satellite with leading g
AMINA Becomes the First Regulated Bank to Integrate Leading Crypto Payments Network, Mesh16.7.2026 09:30:00 EEST | Press release
AMINA Bank AG (“AMINA”), a Swiss Financial Market Supervisory Authority (FINMA)-regulated crypto bank with global reach, today becomes the first regulated bank to integrate Mesh, the leading crypto payments network. The integration embeds Mesh’s verified deposit technology directly into AMINA’s online banking platform. This allows clients to verify wallet ownership, and deposit stablecoins and digital assets in a single, streamlined flow across more than 300 wallet providers. No more copying wallet addresses by hand, switching between external tools, or completing the multi-step verification the process historically required. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260715917516/en/ AMINA is the first regulated bank on Mesh. Myles Harrison, Chief Product Officer at AMINA, said: “Despite the incredible progress the industry has made in institutional adoption, crypto remains difficult to move safely and efficiently betwe
Garvan Institute of Medical Research Joins Parse Biosciences’ Certified Service Provider Network15.7.2026 23:00:00 EEST | Press release
Parse Biosciences, a QIAGEN company, and the leader in scalable and accessible single cell sequencing, today announced that the Genomics Platform Core Facility within the Garvan Institute of Medical Research has joined its Certified Service Provider (CSP) Program. The partnership broadens access to high-quality, scalable single cell sequencing across Australia, the wider Asia-Pacific region, and beyond. Garvan is one of Australia's preeminent medical research institutions, with the Genomics Platform having deep experience in cell sorting, capture, and sequencing. As a Certified Service Provider, Garvan will offer Parse's Evercode WT kits to researchers across the region. "We see a growing number of requests for Parse projects and find the technology easy to implement and run, generating great data," said Chris O'Keeffe, Cellular Genomics Lead at the Garvan Institute. "Garvan is one of the most respected biomedical research institutions in the world, and we're honored to welcome them to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom